Modified protocol for enhanced recovery after surgery is beneficial for Chinese cancer patients undergoing pancreaticoduodenectomy
Metrics: PDF 1119 views | HTML 1765 views | ?
Xiaxing Deng1,*, Xi Cheng1,*, Zhen Huo1,*, Yuan Shi1, Zhijian Jin1, Haoran Feng1, Yue Wang1, Chenlei Wen1, Hao Qian1, Ren Zhao1, Weihua Qiu1, Baiyong Shen1 and Chenghong Peng1
1Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
*These authors have contributed equally to this work
Chenghong Peng, email: firstname.lastname@example.org
Baiyong Shen, email: email@example.com
Weihua Qiu, email: firstname.lastname@example.org
Keywords: enhanced recovery after surgery, pancreatic cancer, pancreaticoduodenectomy, perioperative management
Received: November 04, 2016 Accepted: May 04, 2017 Published: May 23, 2017
Radical surgical resection remains the only effective treatment for advanced pancreatic cancer. Effective protocols for recovery from post-operative complications that result in high rates of morbidity and mortality are therefore essential. The enhanced recovery after surgery (ERAS) protocol is an interdisciplinary multimodal concept based on modern anesthesia and analgesia combined with other fast rehabilitation parameters. It was first applied in the field of elective colorectal surgery, and eventually extended to several surgical diseases. In this study, we investigated the feasibility and safety of implementing the ERAS protocol in patients undergoing pancreaticoduodenectomy (PD). We randomly divided 159 patients who underwent PD into two groups who were managed using either ERAS or the conventional protocol. We observed that in those treated with the ERAS protocol several post-operative recovery factors were greatly improved, and there were no complications requiring readmission. We therefore propose that ERAS can improve post-operative recovery of PD patients and shorten the waiting time to chemotherapy, which may improve the overall survival of surgically treated pancreatic cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.